AR025780A1 - VASOPRESINE ANTAGONIST FORMULATION AND ITS PROCESS - Google Patents

VASOPRESINE ANTAGONIST FORMULATION AND ITS PROCESS

Info

Publication number
AR025780A1
AR025780A1 ARP000105036A ARP000105036A AR025780A1 AR 025780 A1 AR025780 A1 AR 025780A1 AR P000105036 A ARP000105036 A AR P000105036A AR P000105036 A ARP000105036 A AR P000105036A AR 025780 A1 AR025780 A1 AR 025780A1
Authority
AR
Argentina
Prior art keywords
vasopresine
component
pharmaceutically acceptable
antagonist formulation
formulations
Prior art date
Application number
ARP000105036A
Other languages
Spanish (es)
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of AR025780A1 publication Critical patent/AR025780A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta provee formulaciones de N-[4-(5H-pirrolo[2,1-c][1,4]benzodiazepin-10(11H)ilcarbonil)-3-clorofenil]-5-fluoro-2-metilbenzamida, o su salfarmacéuticamente aceptable, y a los procesos para prepararlas, las formulaciones comprenden entre alrededorde l 1% y alrededor del 20% del ingrediente activo,entre alrededor del 1% y alrededor del 18% de un componente surfactante, entre alrededor del 50% y alrededor del 80% de un componente de uno o más polietilénglicoles, entre alrededor del 1% yalrededor del 20% de un componente de uno o más ésteres de ácido graso de sacarosa y/o polivinilpirrolidona y,opcionalmente, uno o más conservantes o anti-oxidantes farmacéuticamente aceptables.It provides formulations of N- [4- (5H-pyrrolo [2,1-c] [1,4] benzodiazepin-10 (11H) ylcarbonyl) -3-chlorophenyl] -5-fluoro-2-methylbenzamide, or its pharmaceutically acceptable, and to the processes to prepare them, the formulations comprise between about 1% and about 20% of the active ingredient, between about 1% and about 18% of a surfactant component, between about 50% and about 80% of a component of one or more polyethylene glycols, between about 1% and about 20% of a component of one or more esters of sucrose fatty acid and / or polyvinyl pyrrolidone and, optionally, one or more pharmaceutically acceptable preservatives or anti-oxidants.

ARP000105036A 1999-09-27 2000-09-26 VASOPRESINE ANTAGONIST FORMULATION AND ITS PROCESS AR025780A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40577299A 1999-09-27 1999-09-27

Publications (1)

Publication Number Publication Date
AR025780A1 true AR025780A1 (en) 2002-12-11

Family

ID=23605168

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105036A AR025780A1 (en) 1999-09-27 2000-09-26 VASOPRESINE ANTAGONIST FORMULATION AND ITS PROCESS

Country Status (18)

Country Link
EP (1) EP1216033A1 (en)
JP (1) JP2003510269A (en)
KR (1) KR20020039354A (en)
CN (1) CN1391466A (en)
AR (1) AR025780A1 (en)
AU (1) AU7615000A (en)
BR (1) BR0014351A (en)
CA (1) CA2388474A1 (en)
CZ (1) CZ20021083A3 (en)
EA (1) EA200200414A1 (en)
HK (1) HK1045109A1 (en)
HU (1) HUP0202972A3 (en)
IL (1) IL148541A0 (en)
MX (1) MXPA02003189A (en)
NO (1) NO20021475L (en)
PL (1) PL354282A1 (en)
WO (1) WO2001022945A1 (en)
ZA (1) ZA200203312B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
JP4632288B2 (en) * 2002-02-27 2011-02-16 塩野義製薬株式会社 Solid formulation with improved absorption of poorly water-soluble drugs
JP5873375B2 (en) * 2012-04-03 2016-03-01 中日本カプセル 株式会社 Soft capsule and method for producing soft capsule

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516774A (en) * 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US6287594B1 (en) * 1998-01-20 2001-09-11 Edward S. Wilson Oral liquid compositions

Also Published As

Publication number Publication date
HUP0202972A3 (en) 2003-07-28
CZ20021083A3 (en) 2002-06-12
HK1045109A1 (en) 2002-11-15
EP1216033A1 (en) 2002-06-26
ZA200203312B (en) 2003-12-31
IL148541A0 (en) 2002-09-12
NO20021475L (en) 2002-04-16
PL354282A1 (en) 2003-12-29
KR20020039354A (en) 2002-05-25
NO20021475D0 (en) 2002-03-25
HUP0202972A2 (en) 2002-12-28
AU7615000A (en) 2001-04-30
MXPA02003189A (en) 2002-09-30
EA200200414A1 (en) 2002-12-26
CA2388474A1 (en) 2001-04-05
CN1391466A (en) 2003-01-15
WO2001022945A1 (en) 2001-04-05
JP2003510269A (en) 2003-03-18
BR0014351A (en) 2002-06-11

Similar Documents

Publication Publication Date Title
ECSP055528A (en) PHARMACEUTICAL COMPOSITION THAT HAS A UNIFORM DISTRIBUTION AND POWER OF FARMACO
DK1021204T3 (en) Bioadhesive compositions and methods for topical administration of active agents
ES2178037T3 (en) CYCLOSPORINE DERIVATIVES, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
CA2271196A1 (en) Pharmaceutical compositions of hiv protease inhibitors with improved oral bioavailability
UY26186A1 (en) METALOPROTEASE INHIBITORS
WO2001007049A3 (en) Ophthalmic composition comprising ketotifen
ES2065846B1 (en) PHARMACEUTICAL FORMULATION BASED ON A STEROID OR NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTIBIOTIC BELONGING TO THE GIRASE DNA INHIBITORS GROUP FOR ITS TOPICAL OPHTHALMIC USE.
AR025780A1 (en) VASOPRESINE ANTAGONIST FORMULATION AND ITS PROCESS
ES2134237T3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING URSODESOXICOLICO ACID.
WO2003082881A3 (en) Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors
PA8525801A1 (en) PIRAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS TO MODULATE AND / OR INHIBIT THE ACTIVITY OF ERAB / HADH2
ES2175827T3 (en) TRANSMUCOUS FORMULATIONS OF LEVOSIMENDANO.
EA200200415A1 (en) COMPOSITION OF PHARMACEUTICAL MEDIA
WO2001034129A3 (en) Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use
WO2001022969A3 (en) Vasopressin agonist formulation and process
ECSP941088A (en) COMPOSITIONS
AU4340796A (en) Use of lauric acid esters as potency increasing agents for active substances
FI932654A (en) Hydroxamsyraderivat, som hindrar lipoxigenas
DE69828522D1 (en) ANTITROMOMBOTIC AGENTS
ES2121109T3 (en) SHAMPOO COMPOSITION.
AU3548901A (en) Veterinary compositions for the treatment of parasitic diseases
RU2008115908A (en) PHARMACEUTICAL COMPOSITION CONTAINING HYALURONIDASE AND LIPOSOMES FOR EXTERNAL USE
AU1022401A (en) Cleaning agents which contain surfactants and enzyme inhibitors
CO5271689A1 (en) COMPOUND AND METHOD FOR PAIN TREATMENT
AR005730A1 (en) FORM OF FANCICLOVIR, PROCEDURE FOR PREPARING IT, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT AND METHOD FOR THE TREATMENT OR PROPHYLAXIS OF VIRAL INFECTIONS AND THE USE OF SUCH FORM -FANCICLOVIR MONOIDRATE.